secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2021-09-23T23:59:59+00:00
Accession:  0001564590-21-048621
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera: EU Joint Procurement for up to 220,000 doses of bamlanivimab/etesevimab
--------------------------------------------------------------------------------

- EC and Lilly agree to supply up to 220,000 doses of bamlanivimab plus etesevimab for COVID-19 in EU/EEA patients 12+ at risk.
- Therapy neutralizes Delta variant causing >95% of new EU/EEA infections.
- In US, therapy treated >535,000 patients; estimated 25,000 hospitalizations and 10,000 lives saved.
- Participating EU/EEA countries can purchase directly from Lilly after national or EU authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021048621/0001564590-21-048621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021048621/abcl-8k_20210921.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-048621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer